MYGN
Overvalued by 110.3% based on the discounted cash flow analysis.
Market cap | $2.29 Billion |
---|---|
Enterprise Value | $2.22 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-3.18 |
Beta | 1.53 |
Outstanding Shares | 90,507,981 |
Avg 30 Day Volume | 787,033 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -8.68 |
---|---|
PEG | 16.54 |
Price to Sales | 3.18 |
Price to Book Ratio | 3.18 |
Enterprise Value to Revenue | 2.87 |
Enterprise Value to EBIT | -18.45 |
Enterprise Value to Net Income | -10 |
Total Debt to Enterprise | 0.02 |
Debt to Equity | 0.05 |
No data
No data
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...